Status:
COMPLETED
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administere...
Eligibility Criteria
Inclusion
- Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China
- Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed
- Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization
- Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator
- Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²)
Exclusion
- Are pregnant, or intend to become pregnant or to breastfeed during the study
- Have known allergies to related compounds of eloralintide
- Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator:
- Supine BP \> 160/90 millimeter mercury (mmHg)
- Supine pulse rate \< 50 or \> 100 beats per minute (bpm)
- Orthostatic hypotension
- Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs
- Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history
- Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study
- Have a history of chronic medical conditions involving the heart, liver, or kidneys
- Have a medical history or current evidence of clinically significant cardiac condition
Key Trial Info
Start Date :
April 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06916091
Start Date
April 21 2025
End Date
September 9 2025
Last Update
November 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lilly Centre for Clinical Pharmacology
Singapore, Singapore, 138623